---
title: "Pre-market trend | Regeneron Pharma (REGN) plummeted nearly 10% on May 18, is short interest accelerating?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286816984.md"
description: "Yesterday, Regeneron Pharma's stock price plummeted 9.82% to $629.68, with a large bearish candlestick engulfing the gains of the previous days. The 5-day and 10-day moving averages were decisively breached, severely damaging the short-term bullish arrangement. The MACD daily line issued a bearish signal below the zero axis, indicating that selling pressure has shifted from testing to active attack, with the short-term trend rapidly weakening. The trading volume reached $1.87 billion, far exceeding the recent average level, showing clear signs of panic selling, with bears completely in control"
datetime: "2026-05-19T13:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286816984.md)
  - [en](https://longbridge.com/en/news/286816984.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286816984.md)
---

# Pre-market trend | Regeneron Pharma (REGN) plummeted nearly 10% on May 18, is short interest accelerating?

Yesterday, Regeneron Pharma's stock price plummeted 9.82% to $629.68, with a large bearish candlestick engulfing the gains of the previous days. The 5-day and 10-day moving averages were decisively breached, severely damaging the short-term bullish arrangement. The MACD daily line issued a bearish signal below the zero axis, indicating that selling pressure has shifted from testing to active attacks, with the short-term trend rapidly weakening. The trading volume reached $1.87 billion, far exceeding the recent average level, showing clear signs of panic selling, with bears completely in control

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [Leerink Partners Reiterates "Market Perform" Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)](https://longbridge.com/en/news/286773280.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Regeneron Announces Strategic Collaboration With Parabilis Medicines To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas](https://longbridge.com/en/news/286759146.md)
- [Regeneron's Phase 3 Melanoma Trial Shows Numeric PFS Benefit But Misses Statistical Significance](https://longbridge.com/en/news/286662524.md)